Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
for
Glaucoma, Open-Angle, Ocular Hypertension
Location: New Smyrna Beach FL, Morrow GA, Roswell GA,
Sponsor: Amneal Pharmaceuticals, LLC
Sex: All
Age: 18+
Code: NCT05401357
Phase 3, Recruiting
Active & Responsive
Early Life Feeding Exposure and Infant Immune and Health Status.
for
Maternal Behavior, Maternal Obesity, Breast Milk Collection,
Location: Moscow ID
Sponsor: University of Idaho
Sex: Female
Age: 18+
Code: NCT05986539
Recruiting
Active & Responsive
Risk Factors in Early Multiple Sclerosis
for
Multiple Sclerosis, Magnetic Resonance Imaging, Biomarkers,
Location: Aurora CO
Sponsor: University of Colorado, Denver
Sex: All
Age: 18 - 30
Code: NCT03586986
Recruiting
Active & Responsive
Met Non Small Cell Cancer Registry (MOMENT)
for
Cancer
Location: Quebec, Ottawa, Fort Lauderdale FL, Toronto,
Sponsor: EMD Serono Research & Development Institute, Inc.
Sex: All
Age: 0+
Code: NCT05376891
Recruiting
Active & Responsive
Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
for
Osteosarcoma
Location: Cleveland OH
Sponsor: MedPacto, Inc.
Sex: All
Age: 12+
Code: NCT05588648
Phase 1, Phase 2, Recruiting
Active & Responsive
Use of BMAC With Hip Arthroscopy Treatment of FAI and Labral Tear
Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell
for
Cell Therapy
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT06575374
Phase 2, Recruiting
Active & Responsive
The ROSE Scale-up Study: Informing a Decision About ROSE as Universal PPD Prevention
for
Postpartum Depression
Location: Flint MI
Sponsor: Michigan State University
Sex: Female
Age: 18+
Code: NCT05700760
Recruiting
Active & Responsive
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
for
Breast Neoplasms
Location: Rimouski, Boston MA, Quebec, Stony Brook NY,